Liver/Biliary Disorders News

Although use of glucagon-like peptide-1 agonists for diabetes and weight loss has soared with indications now expanding into liver diseases, specifically metabolic dysfunction-associated steatohepatitis, the jury is still out on its benefit.

A continuous risk score accurately predicted waitlist dropout and post-liver transplantation outcomes in patients with hepatocellular carcinoma, even over the course of several UNOS policy changes, researchers reported.

In a new clinical practice guideline, the ACG has provided evidence-based recommendations for the diagnosis and management of the most common focal liver lesions among individuals without known liver disease.

Maralixibat improved cholestatic pruritis and reduced serum bile acids in pediatric patients with progressive familial intrahepatic cholestasis, regardless of disease genotype, according to data from the MARCH-PFIC trial.

The new United Network for Organ Sharing liver allocation policy has resulted in a significant increase in the number and cost of liver imports, with greater costs incurred by low-income states and underserved areas, according to analysis.

The FDA granted marketing authorization for Cepheid’s Xpert HCV test and GeneXpert Xpress System, the first rapid test for hepatitis C virus intended for use in point-of-care settings.

Researchers have developed a data-driven, systematic approach for classification of the most potentially hepatotoxic medications based on incidence rates of severe acute liver injury, rather than published case report counts.

Interim analyses of two phase 2b studies of volixibat support its use as potential treatment for patients with primary biliary cholangitis and primary sclerosing cholangitis, according to a press release from Mirum Pharmaceuticals.

Patients with metabolic dysfunction-associated steatohepatitis and advanced fibrosis treated with tirzepatide achieved significant disease resolution without worsening of fibrosis, compared with those on placebo, according to research.

Survodutide has an “acceptable safety profile” in patients with metabolic dysfunction-associated steatohepatitis with compensated and decompensated cirrhosis, with no dose reduction needed based on pharmacokinetics, according to data.